Publications
NeuroPerspective (formerly NeuroInvestment)
Our monthly journal covering the cutting-edge therapies being developed for disorders of the central nervous system, including Alzheimer's, Parkinson's, stroke, brain injury, schizophrenia, and depression--and the companies pursuing them. It enjoys worldwide readership and kudoes for its 'no-holds-barred' evaluations. |
|
$2200 for 1 year subscription | |
Private CNS Company Review 2012
|
|
The 2012 edition of the Private CNS Company Review offers a unique database of information for Business Development professionals evaluating strategic opportunities for inlicensing, outlicensing, M&A, collaboration, and financing. Information and expert opinion regarding private companies specializing in the development of novel therapeutics for neurological/psychiatric disorders. PCNS describes and appraises scientific platforms; clinical/preclinical activity; contact information; alliances; financing; prospects, and licensing opportunities. It also assesses the best M&A prospects amongst these private CNS companies. Produced in pdf form for easy searchability. The 2012 edition reviews 138 companies in 188 pages.
| ||
Startup companies can contact us for pricing options | |||
CNS 2011: Therapeutics/ Licensing Database
|
|
1) CNS 2011 Neurotherapeutics compiles NI Research's comprehensive reviews of all major psychiatric and neurological indications, and the relevant therapeutics programs. All reviews are fully updated and revised. This database provides strategic planners and Business Development professionals with a complete review of the neuro and psychopharmaceutical universe of therapies in development, in a single searchable pdf. 2) Licensing Database: This evaluation reviews the neurotherapeutics programs and licensing agendas for all major and midsize companies in the CNS area. Opportunities for opportunities for licensing and M&A are appraised. This provides a vital targeting resource for licensing efforts on both sides of the transaction, potential licensors and licensees. There is nothing else like CNS 2011, at any price. | |
Startup companies can contact us for pricing options | ||
